A genomic and epigenomic atlas of prostate cancer in Asian populations

Jing Li, Chuanliang Xu, Hyung Joo Lee, Shancheng Ren, Xiaoyuan Zi, Zhiming Zhang, Haifeng Wang, Yongwei Yu, Chenghua Yang, Xiaofeng Gao, Jianguo Hou, Linhui Wang, Bo Yang, Qing Yang, Huamao Ye, Tie Zhou, Xin Lu, Yan Wang, Min Qu, Qingsong Yang, Wenhui Zhang, Nakul M. Shah, Erica C. Pehrsson, Shuo Wang, Zengjun Wang, Jun Jiang, Yan Zhu, Rui Chen, Huan Chen, Feng Zhu, Bijun Lian, Xiaoyun Li, Yun Zhang, Chao Wang, Yue Wang, Guangan Xiao, Junfeng Jiang, Yue Yang, Chaozhao Liang, Jianquan Hou, Conghui Han, Ming Chen, Ning Jiang, Dahong Zhang, Song Wu, Jinjian Yang, Tao Wang, Yongliang Chen, Jiantong Cai, Wenzeng Yang, Jun Xu, Shaogang Wang, Xu Gao (), Ting Wang () and Yinghao Sun ()
Additional contact information
Jing Li: Second Military Medical University
Chuanliang Xu: Second Military Medical University
Hyung Joo Lee: Washington University School of Medicine
Shancheng Ren: Second Military Medical University
Xiaoyuan Zi: Second Military Medical University
Zhiming Zhang: Novogene Co, Ltd
Haifeng Wang: Second Military Medical University
Yongwei Yu: Second Military Medical University
Chenghua Yang: Second Military Medical University
Xiaofeng Gao: Second Military Medical University
Jianguo Hou: Second Military Medical University
Linhui Wang: Changzheng Hospital, Second Military Medical University
Bo Yang: Second Military Medical University
Qing Yang: Second Military Medical University
Huamao Ye: Second Military Medical University
Tie Zhou: Second Military Medical University
Xin Lu: Second Military Medical University
Yan Wang: Second Military Medical University
Min Qu: Second Military Medical University
Qingsong Yang: Changhai Hospital, Second Military Medical University
Wenhui Zhang: Second Military Medical University
Nakul M. Shah: Washington University School of Medicine
Erica C. Pehrsson: Washington University School of Medicine
Shuo Wang: Zhejiang University
Zengjun Wang: the First Affiliated Hospital of Nanjing Medical University
Jun Jiang: Third Military Medical University
Yan Zhu: Second Military Medical University
Rui Chen: Second Military Medical University
Huan Chen: Second Military Medical University
Feng Zhu: Second Military Medical University
Bijun Lian: Second Military Medical University
Xiaoyun Li: Novogene Co, Ltd
Yun Zhang: Second Military Medical University
Chao Wang: Second Military Medical University
Yue Wang: Shanghai Key Laboratory of Cell Engineering
Guangan Xiao: Second Military Medical University
Junfeng Jiang: Shanghai Key Laboratory of Cell Engineering
Yue Yang: Second Military Medical University
Chaozhao Liang: First Affiliated Hospital of Anhui Medical University
Jianquan Hou: First Affiliated Hospital of Soochow University
Conghui Han: The Affiliated Xuzhou Hospital of Medical College of Southeast University
Ming Chen: Zhongda Hospital, Southeast University
Ning Jiang: Second Military Medical University
Dahong Zhang: Zhejiang Provincial People’s Hospital, Hangzhou Medical College
Song Wu: Shenzhen Luohu People’s Hospital
Jinjian Yang: First Affiliated Hospital of Zhengzhou University
Tao Wang: First Affiliated Hospital of Zhengzhou University
Yongliang Chen: Shaoxing Central Hospital
Jiantong Cai: Shishi Hospital
Wenzeng Yang: The Affiliated Hospital of Hebei University
Jun Xu: Huadong Hospital, Fudan University
Shaogang Wang: Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology
Xu Gao: Second Military Medical University
Ting Wang: Washington University School of Medicine
Yinghao Sun: Second Military Medical University

Nature, 2020, vol. 580, issue 7801, 93-99

Abstract: Abstract Prostate cancer is the second most common cancer in men worldwide1. Over the past decade, large-scale integrative genomics efforts have enhanced our understanding of this disease by characterizing its genetic and epigenetic landscape in thousands of patients2,3. However, most tumours profiled in these studies were obtained from patients from Western populations. Here we produced and analysed whole-genome, whole-transcriptome and DNA methylation data for 208 pairs of tumour tissue samples and matched healthy control tissue from Chinese patients with primary prostate cancer. Systematic comparison with published data from 2,554 prostate tumours revealed that the genomic alteration signatures in Chinese patients were markedly distinct from those of Western cohorts: specifically, 41% of tumours contained mutations in FOXA1 and 18% each had deletions in ZNF292 and CHD1. Alterations of the genome and epigenome were correlated and were predictive of disease phenotype and progression. Coding and noncoding mutations, as well as epimutations, converged on pathways that are important for prostate cancer, providing insights into this devastating disease. These discoveries underscore the importance of including population context in constructing comprehensive genomic maps for disease.

Date: 2020
References: Add references at CitEc
Citations: View citations in EconPapers (4)

Downloads: (external link)
https://www.nature.com/articles/s41586-020-2135-x Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:580:y:2020:i:7801:d:10.1038_s41586-020-2135-x

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/s41586-020-2135-x

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().